Osteoarthritis (OA) is a highly prevalent joint disease characterized by the degeneration of articular cartilage, which serves as a protective cushion within the joint, leading to pain and impaired joint mobility.
Current therapeutic modalities (e.g., exercise therapy, analgesics, hyaluronic acid injections, and others) primarily focus on 'symptomatic therapy,' which merely suppresses pain and cannot restore damaged cartilage to its original condition.
The current focus is on 'cartilage regeneration' through 'stem cell therapy'.
Of particular interest are Wharton's jelly-derived mesenchymal stem cells (WJ-MSC). These are stem cells extracted from Wharton's jelly, the gelatinous tissue within the umbilical cord, and are characterized by their ability to yield a large quantity of young and healthy cells.
These WJ-MSCs demonstrate low immunogenicity, even when allogeneic, and are thus promising as a regenerative therapeutic material with minimal burden on the patient's body.
Joint Pain Relief and Improved Joint Function
The injection of Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) into joints has been observed to alleviate knee pain and improve daily mobility. A growing number of reports corroborate these findings.
For instance, in a study where patients with knee osteoarthritis were injected with WJ-MSC, significant pain reduction was observed at one-year follow-up. Furthermore, scores reflecting joint mobility (WOMAC score and Lequesne index) also demonstrated clear improvement. Patient satisfaction, with individuals reporting feeling "better," also increased, which was consistent with improvements in objective MRI findings and inflammatory markers in the synovial fluid.
In another Phase I clinical trial, repeated administration of WJ-MSC to patients with relatively mild symptoms led to a reduction in Visual Analog Scale (VAS) pain scores from a mean of 6.0 to 3.5 within 3 months. Additionally, knee function assessment significantly improved from 26.0 to 8.5.
Many patients report improved ease in ascending and descending stairs, and that shopping is no longer burdensome. They also indicate a reduction in the discomfort experienced in daily life due to joint pain.
These findings suggest that WJ-MSC therapy not only alleviates pain but also holds the potential to improve the intrinsic condition of the joint itself. In other words, it can be characterized as a treatment that initiates the repair of degenerating joint cartilage.
Key Point
- WJ-MSC injections significantly reduced pain (VAS score), according to research reports.
- Joint function scores (WOMAC and the Lequesne index) also markedly increased.
- MRI and biochemical markers also demonstrated favorable changes in joint condition.
- Mobility and daily activities are made easier, enhancing quality of life.
- It not only alleviates symptoms but also indicates the potential to restore functional mobility.
Evidence of Cartilage Regeneration and Repair
A major appeal of stem cell therapy is the potential to repair damaged cartilage within the joint itself. In recent research utilizing Wharton's jelly stem cells (WJ-MSCs), this "cartilage regeneration" was indeed observed.
In a study, one year after injecting WJ-MSC into the knee joint, MRI clearly showed an increase in knee cartilage thickness. Notably, clear regeneration was observed in the tibia and femur joint regions, which are particularly susceptible to heavy loading.
Additionally, upon assessment utilizing T2 mapping, a method capable of evaluating cartilage quality via MRI, the cartilage was observed to transition from a soft and degenerated state to one approaching a healthy and elastic condition.
Even within a brief 6-12 month observation period, instances of newly formed cartilage-like tissue were observed in previously degenerated areas, and the condition of the subchondral bone also improved.
This represents a truly revolutionary change, seldom observed in prior medical practice.
Furthermore, even in animal experiments, treatment with WJ-MSC promotes cartilage regeneration, resulting in the recreation of tissue resembling healthy native cartilage.
Key Point
- MRI confirmed increased cartilage thickness.
- T2 mapping also indicates improved cartilage quality.
- The formation of new cartilage-like tissue was observed in the deficient area.
- It has been reported that the condition of the bone beneath the cartilage (subchondral bone) also improved.
- Even in animal experiments, cartilage regeneration closely resembling healthy native cartilage has been confirmed.
Mechanism of Anti-inflammatory Action and Immune Modulation
In osteoarthritis, inflammation occurs in the synovial fluid and intra-articular tissues, leading to pain and cartilage damage. Wharton's jelly mesenchymal stem cells (WJ-MSCs) secrete numerous anti-inflammatory factors to suppress this inflammation.
Of particular interest are IL-10 (Interleukin 10) and TGF-β (Transforming Growth Factor-β).
- IL-10 suppresses the overproduction of inflammatory mediators, thereby preventing tissue damage and the subsequent development of pain and swelling.
- TGF-β not only mitigates hyperactive immune responses but also supports the intrinsic repair capacity of damaged cartilage.
Furthermore, WJ-MSC secretes VEGF (Vascular Endothelial Growth Factor) and HGF (Hepatocyte Growth Factor) to enhance blood flow to the injured site and support tissue regeneration.
From an immunological perspective, WJ-MSCs modulate macrophages, the immune sentinels within joints, shifting them from a pro-inflammatory (M1) to a reparative (M2) phenotype, thereby alleviating inflammation. Furthermore, by inhibiting the activity of T and B lymphocytes and promoting regulatory T cells (Tregs), WJ-MSCs suppress excessive immune responses.
In this manner, WJ-MSC modulates the cytokine network (cell signaling molecules) within the joint, acting as a switch that transitions from "damage" to "repair."
Notably, following WJ-MSC injection, levels of pro-inflammatory mediators in the synovial fluid (TNF-α, IL-1β, IL-6) were reduced, and the balance of fat-derived adipokines (leptin, adiponectin) was also enhanced.
Key Point
- WJ-MSC secretes anti-inflammatory factors such as IL-10 and TGF-β to suppress inflammation.
- VEGF and HGF promote vascularization and tissue regeneration.
- Repolarizing macrophages from a pro-inflammatory to a reparative phenotype, thereby modulating the joint microenvironment.
- Suppressing T and B cell activity and autoimmune inflammation.
- Consequently, it interrupts the inflammatory cycle within the joint and creates an environment conducive to regeneration.
Enhancement of Patient Quality of Life (QOL)
Osteoarthritis pain significantly limits daily activities, causing individuals to withdraw from outdoor activities, hobbies, and even social interactions. Wharton's jelly stem cell therapy (WJ-MSC) has garnered attention as a potential approach to address these life limitations.
For instance, a patient reported diminished pain following WJ-MSC treatment, and observed positive changes such as "I can walk around again" and "I can climb stairs without fear."
In actual clinical research, the following increases in objective values are also reported:
- On the SF-36 (Health Questionnaire), the total score increased by approximately 25% compared to before treatment.
- On the SF-12 (an indicator measuring physical and mental aspects of Quality of Life), the score increased from 39.0 to 46.0.
- Even on a Likert scale evaluating subjective symptom improvement, nearly all patients reported "improved."
In other words, this signifies not merely the absence of pain, but also the restoration of an authentic life. Furthermore, as pain subsides, individuals are able to sleep more soundly, and anxiety and depressive moods are also alleviated in some cases.
Bodily restoration also extends to inner well-being; WJ-MSC therapy can be described as a treatment that supports both.
Key Point
- Following WJ-MSC therapy, many patients experienced a significant improvement in QOL (Quality of Life).
- Indicators such as SF-36 and SF-12 demonstrate improvements in physical and mental health.
- Reports on positive life impacts, such as "I can walk again" and "I can pursue hobbies."
- Pain relief also leads to improved sleep quality and mood stability.
- WJ-MSC therapy is not merely pain treatment, but also actively contributes to the comprehensive rebuilding of lives.
About Safety and Side Effects
Upon hearing "stem cell therapy," some individuals may be concerned about potential side effects or the risk of rejection. However, WJ-MSC has undergone numerous clinical trials worldwide, with the majority confirming its high safety profile.
Allogeneic cells are rarely rejected.
WJ-MSCs are stem cells derived from neonatal umbilical cords. Typically, when allogeneic cells are introduced into the body, the immune system may recognize them as foreign and initiate an attack. However, WJ-MSCs possess properties that do not readily trigger such an immune response.
This is due to the scarcity of immune-recognition molecules (such as MHC class II) on the cell surface. In fact, clinical trials conducted to date have not reported any serious complications resulting from rejection.
Are there any concerns about cancer?
Given the robust proliferative capacity of stem cells, concerns about their potential for tumorigenesis may arise. However, WJ-MSCs have been consistently confirmed in studies to date as non-tumorigenic, meaning they do not possess tumor-forming properties.
No nodule formation has been reported post-administration, and no abnormal proliferation has been detected. Verification is currently underway by multiple domestic and international research institutions, and at present, no serious risks have been confirmed.
Mild side effects may occur.
Following treatment, mild swelling at the injection site, a low-grade fever, or mild fatigue may occur. However, most of these reactions typically resolve spontaneously within a few days.
In fact, in one clinical trial, transient side effects were observed in 5 of 14 participants; however, none deteriorated, and all resolved spontaneously.
In other words, although the possibility of adverse effects exists, most are mild and do not impede daily activities.
Key Point
- WJ-MSCs rarely elicit rejection, even from allogeneic cells.
- No serious adverse events such as cancer (tumor transformation) have been reported.
- Minor reactions, including swelling, fever, and fatigue, were observed, but recovery was rapid.
- Given that the treatment is an injection, it imposes a minimal burden on the body.
- Research into safer and more reliable applications is expected to continue to advance.
Comparison with MSCs from Other Sources (Differences from Adipose Tissue and Bone Marrow)
Gentle treatment with minimal physiological burden.
WJ-MSC is a stem cell that can be extracted from "Wharton's jelly," a tissue within the umbilical cord of a baby. This part is typically discarded after birth, thus posing no burden to either the donor or recipient.
Methods for extracting stem cells from bone marrow or adipose tissue require needle aspiration or surgery, but WJ-MSCs do not carry such pain or risks.
The benefits can be confidently utilized, even when derived from cells of other individuals.
Typically, the introduction of allogeneic cells into the body carries a risk of immune rejection. However, WJ-MSCs exhibit low immunogenicity, meaning they are not readily recognized as foreign. This characteristic enables the confident use of donor-derived cells.
This facilitates the earlier initiation of treatment.
A cell with specialized capacity for cartilage regeneration.
In osteoarthritis, pain is attributed to the degeneration of articular cartilage, which functions as a joint cushion. WJ-MSC is reported to demonstrate a strong potential for regenerating this degenerated cartilage.
A growing number of reports, both domestically and internationally, indicate 'increased joint thickness' and 'smoother movement.'
Key Point
- Safe cells, extractable at birth, no surgery required.
- Infrequently rejected, even when originating from external sources, it can be rapidly utilized.
- Repairing damaged cartilage, addressing the root cause of pain
- Its purpose is not only pain relief but also the achievement of functional joint mobility.
Conclusion
The use of Wharton's jelly-derived MSCs for osteoarthritis treatment is a novel regenerative therapeutic strategy that may target the dual effects of symptom relief and cartilage regeneration.
From current literature, WJ-MSC therapy has demonstrated promising results in alleviating joint pain, improving function, and repairing cartilage, and its effects may extend to disease modification through anti-inflammatory and immune modulation.
Regarding security, the overall performance is excellent and has been confirmed to be achievable without serious adverse effects.
However, there are limitations in the number of cases and uncertainty in long-term outcomes, and the accumulation of evidence through further large-scale randomized controlled trials and long-term follow-up studies is expected.
Representing a treatment that enhances patient Quality of Life (QOL) and prevents the need for future artificial joint replacement, WJ-MSC therapy holds the potential to open new frontiers in the management of osteoarthritis, and further research in this area is highly anticipated.